Table 2.
Subject demographics across three vericiguat drug interaction studies
| Aspirin study PD analysis set (n = 13) | Warfarin study PK/PD analysis set (n = 23) |
SV study PD analysis set (n = 30) |
|
|---|---|---|---|
| Male [n (%)] | 13 (100) | 23 (100) | 30 (100) |
| White [n (%)] | 13 (100) | 23 (100) | 30 (100) |
| Age, years (range) | 32.8 (22–45) | 38.0 (21–55) | 50.2 (40–60) |
| Weight, kg | 79.2 (8.3) | 79.2 (10.6) | 82.1 (9.0) |
| Height, cm | 178.0 (6.6) | 178.7 (6.1) | 179.3 (6.5) |
| BMI, kg/m2 | 25.0 (2.3) | 24.7 (2.6) | 25.5 (2.4) |
Data are expressed as mean (standard deviation) unless otherwise stated
BMI body mass index, PD pharmacodynamic, PK pharmacokinetic, SV sacubitril/valsartan